VIP and rheumatoid arthritis: In vivo and in vitro studies with different mice autoimmune models, human samples from healthy donors and rheumatoid arthritis patients have demonstrated that VIP is able to decrease pathogenic Th1 and Th17 subsets, and favor Th2, Treg and non-pathogenic Th17 subsets.